Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% last ...